NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Kivu Biosciences

Kivu Biosciences

Private
San Mateo, CaliforniaHealthcare & Life Scienceshttps://kivubioscience.com/

Last Round

Series A

Oct 28, 2024

Total Funding Raised

$92M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Kivu Biosciences is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCsolid tumor oncologytargeted cancer therapybiotechclinical-stage biotechlinker-payload technologycancer drug developmentoncology therapeuticsdrug discoveryclinical trialsnext-gen oncologybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kivu Biosciences Comps

Public and private peers based on sector, stage, and business model.

Kivu Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kivu Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 28, 2024
View all Funding Rounds

Key People

Founding team and executive leadership

Mohit Trikha

President COO

Executive Team

Kivu Biosciences Investors

Notable investors and investment history

Kivu Biosciences investors
InvestorRounds
Brabantse Ontwikkelings MaatschappijSeries A
GimvSeries A
M VenturesSeries A
HealthCapSeries A
Novo HoldingsSeries A
BioGeneration VenturesSeries A
Red Tree Venture CapitalSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 22, 2026

    Grew 20% QoQ, from 20 to 24 employees.

  • Apr 15, 2026

    Preclinical data on next-gen ADC programs to be presented at AACR 2026.

View all signals

Kivu Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Kivu Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kivu Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Mateo, California
Employee Range25
Year Founded2024
Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.